Retatrutide Research for Obesity
An evidence-based overview of research examining Retatrutide in the context of obesity. This page synthesizes findings from peer-reviewed literature.
Research Summary
In a phase 2 obesity trial, retatrutide showed up to 24.2% mean weight loss at 48 weeks (12mg dose), with 93% of participants achieving at least 10% weight loss and 83% achieving at least 15%. The newest verified paper in this window (PMID 42608321) is a phase 2 post-hoc biomarker analysis, not a TRIUMPH efficacy result. Lilly has reported TRIUMPH obesity toplines, but detailed peer-reviewed phase 3 obesity results were not located in this review.
Referenced Studies
Click any PMID to view the full study on PubMed.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Always consult a healthcare provider before making health decisions.